TDThorsten Drews

Thorsten Drews

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thorsten Drews has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Transapical aortic valve implantation in patients with severely depressed left ventricular function

    by Axel Unbehaun, Miralem Pasic, Semih Buz, Stephan Dreysse, Marian Kukucka, Roland Hetzer, Thorsten Drews


  • TAVI for Pure Aortic Valve Insufficiency in a Patient With a Left Ventricular Assist Device

    by Giuseppe D'Ancona, Miralem Pasic, Semih Buz, Thorsten Drews, Stephan Dreysse, Roland Hetzer, Axel Unbehaun


  • Open Access

    Transcatheter aortic valve implantation after previous coronary artery bypass grafting: a potential gold standard of care

    by Thorsten Drews

    Ducrocq et al. [1] present in their article the results of 201 patients undergoing transcatheter aortic valve implantation (TAVI). The group was divided into 54 patients with previous coronary artery bypass grafting (CABG) and 147 without. The perioperative and postoperative results were compared. The authors conclude that the TAVI procedure may be ‘an attractive option in the population of high-risk patients with aortic stenosis and previous CABG’. They should be congratulated for achieving these encouraging results. Nevertheless, their article suggests several questions.


    • 1 November 2011
      • Vol. 20  (6) , 711-4

    Transapical aortic valve implantation and 'off-pump' arterial coronary bypass in a patient with a porcelain aorta.

    by Miralem Pasic, Axel Unbehaun, Semih Buz, Thorsten Drews, Roland Hetzer

    A simple hybrid procedure, namely transapical aortic valve implantation combined with 'off-pump' coronary artery bypass using an internal thoracic artery, was performed in a patient with porcelain aorta, aortic valve stenosis and coronary artery disease. This approach does not require cardiopulmonary bypass, and avoids aortic or peripheral arterial cannulation and clamping of the aorta. This hybrid approach can be regarded as a 'new technique' being applied to an 'old idea'.

  • Biological Mitral Valve Prosthesis in a Patient Supported With a Permanent Left Ventricle Assist Device

    by Martin Schweiger, Alexander Stepanenko, Juliane Vierecke, Thorsten Drews, Evgenij Potapov, Roland Hetzer, Thomas Krabatsch

    Mitral valve pathology, especially status postvalve replacement (biological or mechanical), remains challenging in patients suffering from end-stage heart failure and undergoing left ventricular assist device (LVAD) placement due to several factors (potential source for thromboembolic complications, risk for structural deterioration of the biological prosthesis leading to stenosis, and inadequate LVAD preload). We report a case of long-term LVAD support in a patient with a previously implanted biological mitral valve prosthesis. During LVAD insertion, the valve was left in place, and it functioned well until the death of the patient 3 years later. The patient remained free of any valve-related complications.

  • Herzinsuffizienz – Technische Möglichkeiten und Grenzen der mechanischen Kreislaufunterstützung

    by Thomas Krabatsch, Martin Schweiger, Alexander Stepanenko, Thorsten Drews, Evgenij Potapov, Juliane Vierecke, Beate Jurmann, Miralem Pasic, Yu-Guo Weng, Michael Huebler, et al.

    Mit Kunstherzsystemen (VAD) können der linke (LVAD), rechte (RVAD) bzw. beide Ventrikel des Herzens (BVAD) unterstützt werden. Traditional werden VAD-Systeme als Überbrückung bis zur Herztransplantation (BTT) implantiert; allerdings steigen in den letzten Jahren die Zahlen der permanenten Kreislaufunterstützung (DT) an. Eine Explantation eines VAD-Systems als „bridge to recovery“ (BTR) kommt nur für wenige Patienten in Fragen. Patientenselektion, prä- und intraoperatives Management sowie der Zeitpunkt der VAD-Implantation bestimmen den Erfolg dieser Therapie. Ventricular assist devices (VAD) to support the left (LVAD), the right (RVAD) or both ventricles (BVAD) have emerged as one standard of care for advanced heart failure patients. Initially used to bridge patients to transplantation (BTT) they are now more frequently implanted as permanent support (destination therapy, DT). Bridge to recovery (BTR) is a valid option for only a small number of patients. Although there are different devices available, patient selection, preoperative and intraoperative management, and the timing of VAD implantation are the elements critical to successful circulatory support.


  • Transcranial Doppler Sound Detection of Cerebral Microembolism during Transapical Aortic Valve Implantation

    by T. Drews, M. Pasic, S. Buz, A. Unbehaun, S. Dreysse, M. Kukucka, A. Mladenow, R. Hetzer

    Objective: Transapical aortic valve implantation (TAVI) is a new method that might reduce the surgical risk of conventional surgical aortic valve replacement in very high-risk patients. Increased downstream microembolization is expected in transapical aortic valve implantation. However, whether it usually occurs, how often, and its clinical relevance are not known. We report the results of ultrasound microembolic signal detection in the middle cerebral artery during the procedure. Methods: Fifty patients (mean age: 80 ± 5 years; mean EuroSCORE: 36 ± 13 %) underwent transapical aortic valve implantation. Intraoperative transcranial Doppler (TCD) sound examination of both middle cerebral arteries (MCA) was used to identify high-intensity transient signals (HITS) and microembolic signals (MES) during seven phases of the procedure. Pre- and postoperative computed tomography of the brain and clinical neurological examinations were performed preoperatively and daily during the first postoperative week. Results: During the procedure, HITS [right MCA: 435 ± 922 (range 9–5765); left MCA: 471 ± 996 (range 24–6432)] and MES [right MCA: 78 ± 172 (range 1–955); left MCA: 62 ± 190 (range 2–1553)] were detected in all patients. Most of the MES were recorded during valvuloplasty [right MCA: 3 ± 5.6 (range 0–31); left MCA: 2 ± 4.9 (range 0–30)] and positioning of the prosthetic valve in the aortic position [right MCA: 6 ± 5 (range 0–22); left MCA: 2 ± 6.9 (range 0–38)]. Postoperatively, there were no clinical signs of new cerebral embolism. Conclusions: Cerebral microemboli were detected by intraoperative transcranial Doppler sound examinations in all patients during transapical aortic valve implantation. Most of the signals were detected during balloon valvuloplasty and delivery of the prosthetic valve.


  • Open Access

    Adult candidates for heart transplantation with larger body surface area have better prognosis on waiting list after progression to critically ill status

    by Takeshi Komoda, Thorsten Drews, Roland Hetzer, Hans B. Lehmkuhl

    Objective: Smaller body size is one of the characteristics of female patients. We analyzed whether lower body surface area (BSA) of adult patients affects their prognosis after listing for heart transplantation (HTx). Methods: Adult candidates (≥18 and ≪65 years) for de novo HTx in our center, who were newly listed as T (transplantable) by Eurotransplant without ventricular assist device (VAD) support between 2000 and 2009 (n = 545), were studied. The patients were divided into two groups: group S (n = 272): BSA ≪ 1.9563 m2 (median value of total patients) and group L (n = 273): BSA ≥ 1.9563 m2. Most female patients (82/84, 97.6%) belong to group S. Among all these patients, 286 progressed to critically ill status, that is, they were listed in urgent status or received a VAD. Actuarial survival rates were studied in each group. Results: Overall survival rates after listing for HTx in group S were comparable to those in group L (43.0% vs 43.7% for 7-year survival, p = 0.95). However, 1-year survival rate on waiting list after progression to critically ill status in group S (58.0%, n = 135) and that of female patients in group S (55.8%, n = 33) were significantly lower than those in group L (67.3%, n = 151, all were men; p = 0.042 and p = 0.044, respectively). After multivariate Cox analysis, BSA ≪ 1.9563 m2 (hazard ratio 2.120, p = 0.0019), serum creatinine (hazard ratio 1.202, p = 0.033), obesity defined as body mass index ≥30 kg m−2 (hazard ratio 2.043, p = 0.0096) and primary use of VAD (hazard ratio 3.243, p ≪ 0.0001) were identified as independent risk factors for mortality on waiting list after progression to critically ill status. One-year survival rate on waiting list after VAD implantation in group S (44.4%, n = 65) and that of female patients in group S (38.1%, n = 14) were significantly lower than those in group L (63.0%, n = 78, all were men; p = 0.020 and p = 0.012, respectively). Conclusions: Adult HTx candidates with lower BSA, including most women, had worse prognosis on waiting list after progression to critically ill status, especially after VAD implantation. As almost all HTx are nowadays performed in critical status, this problem has emerged as important.


  • Open Access

    Trans-apical aortic valve implantation in patients with severe calcification of the ascending aorta???

    by Semih Buz, Miralem Pasic, Axel Unbehaun, Thorsten Drews, Stephan Dreysse, Marian Kukucka, Alexander Mladenow, Roland Hetzer

    Objective: In patients with calcification of the ascending aorta, postoperative stroke and mortality rates remain high after conventional aortic valve replacement, but the results of trans-apical aortic valve implantation in these patients are not known. We evaluate the outcome of trans-apical aortic valve implantation in patients with severely calcified ascending aorta in a single center with expanded procedural experience. Methods: Between April 2008 and July 2010, 258 patients underwent trans-apical aortic valve implantation using Edwards Sapien valve. By computed tomography (CT) scan, we identified 46 (18%) patients with severe calcification of the ascending aorta (16 with porcelain aorta and 30 with severe, but not complete, calcification). Results: Of 46 patients (mean age 77 ± 10 years, range 63–90 years; EuroSCORE (European System for Cardiac Operative Risk Evaluation) 45 ± 22%; STS (Society of Thoracic Surgeons) score 23 ± 13) with calcified aorta, 15 received 23-mm valves and 31 patients 26-mm valves. Primary valve implantation was successful in 44 patients and a second valve was implanted (valve-in-valve) in two. Six patients underwent concomitant interventions (three elective percutaneous coronary intervention (PCI), one off-pump coronary artery bypass (OPCAB), one tricuspid valve reconstruction, and one left-ventricular (LV) aneurysmectomy). The final procedural results showed valve incompetence (trace or grade 1) in 17 (37%) patients and paravalvular leak in 15 (32.6%) (trace in 10 and grade 1 in five). There was no 30-day mortality. Postoperatively, cranial CT showed new cerebral ischemia areas in three patients (6.2%), but only one patient (2.1%) experienced postoperative neurological deficit (temporary aphasia). Survival at 6 and 12 months was 88% and 85.2%, respectively. Conclusions: Trans-apical aortic valve implantation can be performed safely in patients with aortic valve stenosis and severe calcification of the ascending aorta.


  • Long-Term Mechanical Circulatory Support in 198 Patients: Largest Single-Center Experience Worldwide

    by Thorsten Drews, Michael Dandel, Thomas Krabatsch, Evgenij Potapov, Alexander Stepanenko, Ewald Hennig, Hans Brendan Lehmkuhl, Miralem Pasic, Yuguo Weng, Roland Hetzer

    During recent years, mechanical circulatory support (MCS) devices have been increasingly used for long-term support. Nevertheless, problems of embolic and bleeding complication, infections, and technical failure still inhibit successful permanent support. We analyzed the courses of 198 patients who were supported for >1 year by 12 different MCS devices. Of the 198 patients, 87 had first-generation MCS devices (pulsatile), 43 second-generation devices (nonpulsatile with standard bearings), and 68 third-generation devices (nonpulsatile with magnetic bearings), implanted between July 1994 and March 2009. The mean time on support of the total group was ∼ 2 years (690 ± 321 [366-1,875] days). Of the first generation, 83 patients (95%) could be discharged; in the second and third group, all patients could be discharged. Rehospitalizations were observed in all patients. Reasons for readmission were coagulation disorders, wound infections, stroke, and technical failure. Seventy-seven patients received heart transplantation, 66 are still receiving support, 53 died, and two patients have been weaned from the device. All types of devices can be used for extended periods of time. Device- and nondevice-related rehospitalizations were observed in all three groups of patients. Close outpatient monitoring and support are crucial to ensure good long-term results.